A recently approved intracameral phenylephrine and ketorolac 1%/0.3% product is expected to produce better surgical outcomes following cataract surgery or IOL replacement by preventing miosis and reducing intraoperative pain.
New York—Intracameral phenylephrine and ketorolac injection 1%/0.3% (Omidria, Omeros Corp.)—approved by the FDA for its combined properties of maintaining pupil dilation and reducing pain—is expected to provide multiple advantages to both surgeons and patients during cataract surgery or IOL replacement.
“The goal is to maintain intraoperative mydriasis, to reduce inflammation at the time of surgery, and to reduce the pain associated with surgery,” said Eric D. Donnenfeld, MD, who helped in the clinical trials for the product. Dr. Donnenfeld is a founding partner of Ophthalmic Consultants of Long Island and Connecticut and clinical professor ophthalmology, New York University Medical Center, New York.
Phenylephrine, acting as a mydriatic agent, contracts the radial muscle of the iris, while ketorolac inhibits both cyclooxygenase enzymes, providing a reduction in pain through a decrease in the production of prostaglandins.
“This product is in the perfect place at the perfect time, in that surgeons are looking for both better surgical outcomes and ways to make the procedure more comfortable for patients,” Dr. Donnenfeld said. “We know that a well-dilated pupil improves operative results, reduces complications, and reduces total surgical and phacoemulsification time, so patients end up having more rapid return of visual acuity.”